UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 26, 2022 (
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices)
Registrant’s telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
Trading Symbol |
Name of Each Exchange on which Registered | ||
“ |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
The Board of Directors (the “Board”) of IQVIA Holdings Inc. (the “Company”) appointed Leslie Wims Morris and Sheila A. Stamps to the Board on January 24, 2022 and January 26, 2022, respectively. Ms. Wims Morris will serve as a Class III director, and Ms. Stamps will serve as a Class I director. The Board determined that each of Ms. Wims Morris and Ms. Stamps satisfies the New York Stock Exchange definition of “independent director.”
In connection with their respective appointments to the Board, Ms. Wims Morris and Ms. Stamps are both expected to enter into the Company’s standard indemnification agreement with non-management directors, a copy of which is filed as Exhibit 10.8 to the Company’s Current Report on Form 8-K filed on October 3, 2016 and is incorporated herein by reference. Each of Ms. Wims Morris and Ms. Stamps will participate in the non-employee director compensation arrangements established by the Company for non-employee directors, as described under “Director Compensation” in the Company’s proxy statement dated February 26, 2021 for its 2021 annual meeting of stockholders.
Item 7.01. | Regulation FD Disclosure |
The Company issued press releases announcing the appointment of each of Ms. Wims Morris and Ms. Stamps, which are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference.
Item 9.01. | Financial Statements and Exhibits |
Exhibit |
Description | |
99.1 | Press release dated January 24, 2022 | |
99.2 | Press release dated January 26, 2022 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 26, 2022
IQVIA HOLDINGS INC. | ||
By: | /s/ Eric Sherbet | |
Eric Sherbet | ||
Executive Vice President, General Counsel and Secretary |
Exhibit 99.1
News Release
Contacts: | Nick Childs, IQVIA Investor Relations (nick.childs@iqvia.com) | |
+1.973.316.3828 | ||
Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) | ||
+1.484.567.6732 |
Leslie Wims Morris Joins IQVIA Board of Directors
RESEARCH TRIANGLE PARK, N.C. January 24, 2022 IQVIA (NYSE:IQV), a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, announced the appointment of Leslie Wims Morris to its board of directors, effective today.
With more than 25 years of experience in financial services, Wims Morris is currently Managing Director and Head of Corporate Development for JPMorgan Chases Consumer & Community Banking business, which serves more than 60 million households in the U.S. In this role, she leads the development and launch of strategic partnerships with leading technology, payments, e-commerce and fintech companies and participates in firmwide strategic initiatives. She is also a member of the firms investment committee.
I am very pleased to welcome Leslie to our board of directors, said Ari Bousbib, chairman and CEO, IQVIA. Her global experience managing strategic partnerships across a wide range of industries and deep investment expertise will provide a unique and valuable perspective to our company.
Wims Morris is a former Vice President of Executive Partnerships at American Express, Senior Vice President of Strategy and Business Development at Broadridge Financial Solutions and Senior Vice President at Jefferies & Company. She began her career as a Technology M&A Banker at Broadview International. During her career she has worked with numerous global Fortune 100 companies in the consumer retail, telecommunications, and technology industries to develop and execute innovative partnership strategies.
Passionate about the arts, she joined the board of the Dance Theatre of Harlem in 2010 and currently serves as Vice Chairman.
Wims Morris holds a Master of Business Administration from the Harvard Business School and a Bachelor of Arts in English from Yale University.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence delivers powerful insights with speed and agility enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 77,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIAs insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
# # #
Exhibit 99.2
News Release
Contacts: | Nick Childs, IQVIA Investor Relations (nick.childs@iqvia.com) | |
+1.973.316.3828 | ||
Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) | ||
+1.484.567.6732 |
Sheila A. Stamps Joins IQVIA Board of Directors
RESEARCH TRIANGLE PARK, N.C January 26, 2022 IQVIA (NYSE:IQV) today announced the appointment of Sheila A. Stamps to its board of directors, effective today. Ms. Stamps brings more than four decades of strategic, governance and operational management experience. During her extensive career she held senior executive leadership positions in both public and private sector organizations, most recently as a senior investment advisor to the Comptroller of the State of New York for the NYS Common Retirement Fund and as Commissioner on the board of the New York State Insurance Fund, the states largest provider of workers compensation insurance. Prior to this, she was a Managing Director at Bank of America and Managing Director and Executive Management Committee Member at Bank One London (now, JPMorgan Chase).
Ms. Stamps currently serves on the boards of three public companies, including Pitney Bowes, Inc, a leading provider of global shipping & mailing solutions, where she has been a member of the Audit and Compensation committees since 2020; Atlas Air Worldwide Holdings, Inc., a global provider of aircraft and aviation services, since 2018 where she serves as Chair of the Audit and Finance committee; and MFA Financial, Inc, a residential mortgage REIT, where she is a member of the Compensation and Nominating & Governance committees. She previously served on the board of CIT Group, Inc., a publicly traded financial holding company, as a member of the Audit and Nominating & Governance committees from 2014 until its recent merger with First Citizens BancShares, Inc in January 2022.
We are very pleased to welcome Sheila to our board of directors, said Ari Bousbib, chairman and CEO, IQVIA. Her mix of global experience within the public & private sectors and extensive corporate governance experience from her service on public boards across a diverse set of industries will strengthen our board and provide unique benefit to IQVIA.
Ms. Stamps has a BS in Management Sciences from Duke University and an MBA, Finance, from the University of Chicago. She also completed a Fellowship at Harvard Universitys Weatherhead Center for International Affairs. In 2021, she was recognized as a Most Influential Black Corporate Directors by Savoy Magazine and among the 2019 Most Influential Corporate Directors by WomenInc. Magazine.
Following the appointment of Ms. Stamps, the IQVIA Board of Directors will be comprised of 11 directors, ten of whom are independent and four are women.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence delivers powerful insights with speed and agility enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 77,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIAs insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
# # #
RGV+]K#N17'BO0[6(RS:@B1CJQ
M5L#]*%2F]D'M8=RG_P + \*_]!J#\F_PJO85.P>UAW.BAFCN(4FAD62*10RN
MIR&!Z$&LFK:,TW,X:Y ?$)T<1N90FXOV!QG'Y5M["7LO:]#G]O'VOLNIJ5@=
M!E:KXAT_1_EN)"TV,B)!EO\ ZWXUO2P\ZOP['/6Q-.C\3U,+_A8-MOQ]@EV^
MN\9_*NO^SY?S')_:,/Y3=TGQ#I^L?+;R%9@,F*08;_Z_X5RUW%;5*,J5K]3.%2,[V.AK
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M+^5?<']BZ5_T#+3_ +\+_A1[:K_,_O#V%+^5?<']BZ5_T#+3_OPO^%'MJO\
M,_O#V%+^5?<']BZ5_P! RT_[\+_A1[:K_,_O#V%+^5?<']BZ5_T#+3_OPO\
MA1[:K_,_O#V%+^5?<']BZ5_T#+3_ +\+_A1[:K_,_O#V%+^5?<']BZ5_T#+3
M_OPO^%'MJO\ ,_O#V%+^5?<']BZ5_P! RT_[\+_A1[:K_,_O#V%+^5?<']BZ
M5_T#+3_OPO\ A1[:K_,_O#V%+^5?<']BZ5_T#+3_ +\+_A1[:K_,_O#V%+^5
M?<']BZ5_T#+3_OPO^%'MJO\ ,_O#V%+^5?<']BZ5_P! RT_[\+_A1[:K_,_O
M#V%+^5?<']BZ5_T#+3_OPO\ A1[:K_,_O#V%+^5?<']BZ5_T#+3_ +\+_A1[
M:K_,_O#V%+^5?<']BZ5_T#+3_OPO^%'MJO\ ,_O#V%+^5?<']BZ5_P! RT_[
M\+_A1[:K_,_O#V%+^5?<']BZ5_T#+3_OPO\ A1[:K_,_O#V%+^5?<']BZ5_T
M#+3_ +\+_A1[:K_,_O#V%+^5?<']BZ5_T#+3_OPO^%'MJO\ ,_O#V%+^5?<'
M]BZ5_P! RT_[\+_A1[:K_,_O#V%+^5?<']BZ5_T#+3_OPO\ A1[:K_,_O#V%
M+^5?<']BZ5_T#+3_ +\+_A1[:K_,_O#V%+^5?<']BZ5_T#+3_OPO^%'MJO\
M,_O#V%+^5?<']BZ5_P! RT_[\+_A1[:K_,_O#V%+^5?<']BZ5_T#+3_OPO\
MA1[:K_,_O#V%+^5?<']BZ5_T#+3_ +\+_A1[:K_,_O#V%+^5?<']BZ5_T#+3
M_OPO^%'MJO\ ,_O#V%+^5?<']BZ5_P! RT_[\+_A1[:K_,_O#V%+^5?<']BZ
M5_T#+3_OPO\ A1[:K_,_O#V%+^5?<']BZ5_T#+3_ +\+_A1[:K_,_O#V%+^5
M?<']BZ5_T#+3_OPO^%'MJO\ ,_O#V%+^5?<']BZ5_P! RT_[\+_A1[:K_,_O
M#V%+^5?<']BZ5_T#+3_OPO\ A1[:K_,_O#V%+^5?<']BZ5_T#+3_ +\+_A1[
M:K_,_O#V%+^5?<']BZ5_T#+3_OPO^%'MJO\ ,_O#V%+^5?<']BZ5_P! RT_[
M\+_A1[:K_,_O#V%+^5?<']BZ5_T#+3_OPO\ A1[:K_,_O#V%+^5?<']BZ5_T
M#+3_ +\+_A1[:K_,_O#V%+^5?<']BZ5_T#+3_OPO^%'MJO\ ,_O#V%+^5?<'
M]BZ5_P! RT_[\+_A1[:K_,_O#V%+^5?<']BZ5_T#+3_OPO\ A1[:K_,_O#V%
M+^5?<']BZ5_T#+3_ +\+_A1[:K_,_O#V%+^5?<']BZ5_T#+3_OPO^%'MJO\
M,_O#V%+^5?<']BZ5_P! RT_[\+_A1[:K_,_O#V%+^5?<']BZ5_T#+3_OPO\
MA1[:K_,_O#V%+^5?<']BZ5_T#+3_ +\+_A1[:K_,_O#V%+^5?<']BZ5_T#+3
M_OPO^%'MJO\ ,_O#V%+^5?<']BZ5_P! RT_[\+_A1[:K_,_O#V%+^5?<']BZ
M5_T#+3_OPO\ A1[:K_,_O#V%+^5?<']BZ5_T#+3_ +\+_A1[:K_,_O#V%+^5
M?<']BZ5_T#+3_OPO^%'MJO\ ,_O#V%+^5?<']BZ5_P! RT_[\+_A1[:K_,_O
M#V%+^5?<']BZ5_T#+3_OPO\ A1[:K_,_O#V%+^5?<']BZ5_T#+3_ +\+_A1[
M:K_,_O#V%+^5?<']BZ5_T#+3_OPO^%'MJO\ ,_O#V%+^5?<']BZ5_P! RT_[
M\+_A1[:K_,_O#V%+^5?<']BZ5_T#+3_OPO\ A1[:K_,_O#V%+^5?<']BZ5_T
M#+3_ +\+_A1[:K_,_O#V%+^5?<20Z9I]O*LL%C;Q2+T9(E!'X@4G5G)6
Document and Entity Information |
Jan. 24, 2022 |
---|---|
Cover [Abstract] | |
Amendment Flag | false |
Entity Central Index Key | 0001478242 |
Document Type | 8-K |
Document Period End Date | Jan. 24, 2022 |
Entity Registrant Name | IQVIA HOLDINGS INC. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-35907 |
Entity Tax Identification Number | 27-1341991 |
Entity Address, Address Line One | 4820 Emperor Blvd. |
Entity Address, City or Town | Durham |
Entity Address, State or Province | NC |
Entity Address, Postal Zip Code | 27703 |
City Area Code | (919) |
Local Phone Number | 998-2000 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, par value $0.01 per share |
Trading Symbol | IQV |
Security Exchange Name | NYSE |
Entity Emerging Growth Company | false |
-8?20$3;8T.P
M6BP^0"X99K>]9!:G